Increasing Population With High Rate Of Incidence Fatal STDS Is Driving The Global STD Diagnostics Market

According to a recently published report, the global STD Diagnostics Market is estimated to grow around $200.9billion by 2022 and it is forecasted to grow at the CAGR of 8.9% during 2015-2022. The segmentation of STD diagnostics marketis based on technology, end user industry and geography. The report on STD diagnostics marketForecast 2015-2022 (by STD type, testing devices, location of testing and geography) provides detailed summary as well as predictive analysis of the market.

Full report is availableonglobal STD diagnosticsForecast 2015-2022 (by STD type, testing devices, location of testing and geography)report at http://www.briskinsights.com/report/std-diagnostics-market

Sexually transmitted diseases or (STD) is also known as venereal disease (VD) are one of the most critical disease the world is facing today. Rising population, is correspondingly increasing rate of incidence fatal STDs and client initiated counselling and testing (CICT) are the factors that are driving the growth of diagnostics market of STDs. The growth is mainly contributed by high rate of HIV and HPV testing.Clinical manifestations of STDs like Chlamydia range from Urethritis, Infertility in men to Cervicitis, Endometritis, infertility and Perihepatitis in women are those untreated STDs that display such manifestations more often. Total risk of transmission of Chlamydia infection from male to a female partner is estimated to 40% and from an infected female to male is approx. 30%. This high rate of transmission and huge number of undiagnosed cases has led the world to initiate national screening and also volunteering screening, because of this whole testing, market volume is expected to touch$2.1 billion by 2022.

Scope of the report

1. GLOBAL STD DIAGNOSTIC MARKET BY STD TYPE 2012-2022 ($ BILLION)
1.1. HERPES SIMPLEX VIRUS (HSV) TESTING
1.2. CHANCROID TESTING
1.3. HUMAN PAPILLOMA VIRUS (HPV) TESTING
1.4. P&S SYPHILIS TESTING
1.5. HUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING
1.6. GONORRHEA TESTING
1.7. CHLAMYDIA TESTING

2. GLOBAL STD DIAGNOSTIC MARKET BY TESTING DEVICE 2012-2022 ($ BILLION)
2.1. LABORATORY TESTING DEVICES
2.1.1. PCRS
2.1.2. IMMUNOCHROMATOGRAPHIC CAPILLARY FLOW DIPSTICK TECHNOLOGY (ASSAY)
2.1.3. FLOW CYTOMETERS
2.1.4. DIFFERENTIAL LIGHT SCATTERING
2.1.5. ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
2.2. POINT OF CARE TESTING DEVICES
2.2.1. PHONE CHIPS
2.2.2. MICROFLUIDICS
2.2.3. IMMUNOCHROMATOGRAPHIC TESTS (ICTS)
2.2.4. RAPID DIAGNOSTIC KITS

3. GLOBAL STD DIAGNOSTIC MARKET BY LOCATION OF TESTING DEVICE 2012-2022 ($ BILLION)
3.1. POINT-OF-CARE (POC) TESTING
3.2. LABORATORY TESTING
3.2.1. COMMERCIAL LABORATORY TESTING
3.2.2. PRIVATE LABORATORY TESTING
3.2.3. PUBLIC LABORATORY TESTING

4. GLOBAL STD DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012 - 2022 ($ billion)
4.1. NORTH AMERICA
4.2. EUROPE
4.3. ASIA PACIFIC
4.4. REST OF THE WORLD

5. COMPANY PROFILES
5.1. Abbott
5.2. Beckman Coulter/Danaher
5.3. Becton Dickinson
5.4. BioMerieux
5.5. Bio-Rad
5.6. Enzo Biochem
5.7. ID Biomedical/GSK
5.8. Qiagen
5.9. Roche
5.10. Scienion
5.11. Sequenom
5.12. SeraCare
5.13. Siemens
5.14. Thermo Fisher
5.15. Wako